FAQ/Help |
Calendar |
Search |
Today's Posts |
12-04-2009, 07:12 PM | #1 | ||
|
|||
Member
|
Neurologix completes all surgical procedures in Phase II Parkinson's disease study
3 December 2009 - US clinical-stage biotechnology company Neurologix Inc (OTC: NRGX) said today it has completed all planned surgeries in an ongoing Phase II study of its gene transfer approach to the treatment of advanced Parkinson's disease. The controlled, double-blind, 44-patient Phase II trial is investigating the safety and efficacy of a novel non-dopamine approach to restore motor function in Parkinson's patients who are sub-optimally responsive to available drug therapy. The company expects to announce initial efficacy results from the trial in mid-2010. The investigators are assessing each of the trial participants over time for treatment effects, with the primary trial endpoint being a clinical assessment of motor function at 6 months using the Unified Parkinson's Disease Rating Scale (UPDRS). All participants in the trial will also be monitored for safety for 12 months following their gene transfer procedure. |
||
Reply With Quote |
"Thanks for this!" says: | Conductor71 (12-04-2009) |
12-04-2009, 08:50 PM | #2 | ||
|
|||
In Remembrance
|
I am glad to see this. They were actively seeking out into the community - I thought i'd be hearing another one not finish.
good news! paula
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Phase III: Pimavanserin In Patients With Parkinson's Disease Psychosis | Parkinson's Disease Clinical Trials | |||
cogane completes Phase 1 in USA | Parkinson's Disease | |||
NeurologiX: Parkinson`s Disease Phase 2 Trials Ongoing novel gene transfer approach | Parkinson's Disease Clinical Trials | |||
Neurologix Phase II recruiting...GAD | Parkinson's Disease | |||
Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track by FDA | Parkinson's Disease |